May 23, 2023 · The Big Pharma is pivoting Mounjaro into a weight loss drug, much like Novo did with Ozempic and Wegovy. Lilly’s therapy, which could be approved in obesity later this year and launch in late ... Pfizer scientists knew they wanted to make an antiviral that would go after the main protease (also known as the 3CL protease) of SARS-CoV-2—the coronavirus that causes COVID-19. Inhibiting a ...Pfizer will move ahead with a pill version of a weight-loss drug as competition heats up for an oral medication that can rival Ozempic and other GLP-1 drugs. ... “This is a big setback” for ...Diabetes is a disease in which the body attacks cells within the pancreas that create insulin, a hormone that regulates blood sugar. Diabetes is a disease in which the body attacks cells within the pancreas that create insulin, a hormone th...Novo Nordisk's weight-loss drug semaglutide, sold as the once-weekly Wegovy shot, was effective as a daily pill in a new study. ... The Pfizer study was smaller than Novo’s late-stage trial and ...May 22, 2023 · People with obesity or who were overweight and had another health problem lost an average of 15.1% of their body weight when assigned to take the pill, compared with a 2.4% loss in a group given a ... Tests with weight loss drugs have shown that initial responders tend to continue to respond, while initial non-responders are less likely to respond even with an increase in dosage. ... (Pfizer, 2020). Contrave is a combination of naltrexone, an opioid antagonist, and bupropion, an aminoketone antidepressant, ...Redotex is a drug that is sometimes prescribed or recommended as a weight loss aid. It is produced in Mexico by the Medix pharmaceutical company and is banned in a number of countries, including the United States.Pfizer CEO Albert Bourla has said that an obesity pill could eventually generate $10 billion each year for the company. Lotiglipron, danuglipron and Novo Nordisk 's blockbuster weight loss ...By Berkeley Lovelace Jr. The weight-loss drug Wegovy can reduce the risk of heart attacks and strokes by 20% in adults with heart disease and obesity, according to new research. The trial is the ...A scientist works at a Pfizer vaccine research and development facility. For drugmaker Pfizer, a fortune amassed in the COVID pandemic is now paving the path to pharma nirvana: a weight loss pill ...Pfizer scientists knew they wanted to make an antiviral that would go after the main protease (also known as the 3CL protease) of SARS-CoV-2—the coronavirus that causes COVID-19. Inhibiting a ...Pfizer stock toppled Monday after the company tossed out a potential diabetes and weight-loss drug that leads to elevated liver enzymes. X That drug, dubbed lotiglipron, was a once-daily pill for ...May 22, 2023 · Shares of Pfizer rose about 4.5% following the news, which comes at a time of increased investor interest in the weight-loss treatment market, which is estimated to reach $100 billion by the end ... This image provided by Eli Lilly on Wednesday, Nov. 8, 2023 shows packaging for their new drug Zepbound. The new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss ...Pfizer is continuing to advance the first full agonist oral GLP-1-RA candidate danuglipron toward late-state development. Danuglipron is the largest oral, small …Dec 1, 2023 · Pfizer said on Friday it was stopping further trials of a twice-daily version of its oral weight-loss drug, danuglipron, dealing a blow to its hopes of becoming an early contender in a market that ... May 23, 2023 · Meanwhile, an oral drug from Pfizer causes a similar amount of weight loss as Ozempic, according to results from a Phase 2 clinical trial, CNBC says. The study results also suggest the Pfizer ... While Pfizer's share price has fallen steadily throughout 2022 and 2023, the share price of Eli Lilly and Company ( LLY ), a company that posted $28bn of revenues in 2022, and $6.3bn of net income ...Redotex is a drug that is sometimes prescribed or recommended as a weight loss aid. It is produced in Mexico by the Medix pharmaceutical company and is banned in a number of countries, including the United States.The drugmaker in June reported late-stage trial data from a high-dose oral version of its drug, semaglutide, helping overweight or obese adults lose 15% of their …Mar 5, 2023 · New weight loss drugs are changing the narrative on obesity, with a push from pharma. By Elaine Chen and Matthew Herper. March 5, 2023. ... Pfizer, which is developing an oral GLP-1, estimates the ... Dec 1, 2023 · What is Pfizer’s weight-loss drug? Known as danuglipron, the diabetes and obesity treatment is in a class of drugs called GLP-1 agonists and mimics a hormone the body releases when a person eats ... A Nov. 3 Facebook post (direct link, archive link) appears to show singer Kelly Clarkson talking about losing a serious amount of weight in a short period of time. The video includes an on-screen ...2 ngày trước ... Pfizer has underperformed the S&P 500, healthcare stocks, and high-yield stocks since 2013. The company's weight-loss pill has faced ...By Berkeley Lovelace Jr. The weight-loss drug Wegovy can reduce the risk of heart attacks and strokes by 20% in adults with heart disease and obesity, according to new research. The trial is the ...More than half of Americans are overweight. If you’re among the many who want to lose some extra pounds, congratulations on deciding to make your health a priority. An abundance of supplements promote weight loss, making it hard to determin...May 31, 2023 · A peer-reviewed study has recently come out on Pfizer's weight-loss treatment, danuglipron. And the study, which is based on phase 2 trial data, is encouraging. Patients with type 2 diabetes who ... May 22, 2023 · Novo Nordisk and Pfizer Inc separately released data on Monday showing that pills from the same class as Novo's increasingly popular weight loss drugs such as Wegovy are about as effective as ... The weight-loss drug will list for $1,059.87 for a month’s supply. It will be available by year end. Lilly’s shares rose less than 1% at 12:33 p.m. in New York.Dec 1, 2023 · Friday’s stock losses tied to pessimism about Pfizer’s weight loss drug potential builds on the narrative hanging over the pharmaceutical giant for all of 2023, as sales dry up in its once ... Weight-loss drug lowers cardiovascular disease risk in new trial of Novo Nordisk’s Wegovy ... Boehringer Ingelheim and Pfizer are also conducting clinical trials of their own incretin agonists.Pfizer stock was falling Friday after the biopharmaceutical company announced that it will not be moving forward with a Phase 3 trial of its weight loss candidate. Pfizer said in a news release ...New weight loss drugs are changing the narrative on obesity, with a push from pharma. By Elaine Chen and Matthew Herper. March 5, 2023. ... Pfizer, which is developing an oral GLP-1, estimates the ...Agonism of the glucagon-like peptide-1 receptor (GLP-1R) results in glycemic lowering and body weight loss and is a therapeutic strategy to treat type 2 diabetes (T2D) and obesity. We developed danuglipron (PF-06882961), an oral small-molecule GLP-1R agonist and found it had comparable efficacy to i …Pfizer's phase two trial on its twice-daily pill followed around 600 obese adults who did not have Type 2 diabetes. The trial examined the drug's effect on weight loss after 26 or 32 weeks, at ...Prescription weight-loss drugs that you can use for more than 12 weeks, called long-term use, lead to major weight loss compared with an inactive treatment that doesn't use medicine, called a placebo. The combination of weight-loss medicine and lifestyle changes leads to greater weight loss than do lifestyle changes alone.Dec 1, 2023 · Friday’s stock losses tied to pessimism about Pfizer’s weight loss drug potential builds on the narrative hanging over the pharmaceutical giant for all of 2023, as sales dry up in its once ... In today’s fast-paced world, finding time to prepare healthy meals can be a challenge. Factor 75 meals offer a convenient and nutritious solution for those looking to lose weight and maintain a healthy lifestyle.By contrast, Pfizer (NYSE:PFE), which announced only a few days ago that it was stopping development of a twice daily version of its experimental weight loss pill, is down 41% this year. Pfizer ...Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides. 12/01/2023 Pfizer said Friday it would not advance development of a twice-daily oral weight-loss drug because of its ...Lotiglipron offered Pfizer a chance to match the dosing regimen of Lilly’s orforglipron, which triggered 14.7% weight loss at 36 weeks, and Novo’s oral semaglutide.Novo Nordisk and Pfizer Inc separately released data on Monday showing that pills from the same class as Novo's increasingly popular weight loss drugs such as Wegovy are about as effective as ...Reprints. Investor’s rabid excitement over a new class of obesity medications has shifted focus in recent weeks, away from the injectables already arriving on the market, and toward the pills ...9 thg 11, 2023 ... AstraZeneca is making a big push into the weight-loss drug market ... Novo Nordisk, Eli Lilly and the US firm Pfizer are also racing to ...Pfizer’ s twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The ...The drug discovery story began Friday, March 13, 2020, when medicinal chemist Dafydd Owen was sent home from his job at Pfizer in Cambridge, Massachusetts. Like many employers at the time, the ...Now, Pfizer stock rising as participants were able to lose about 10 pounds over the course of 16 weeks versus 9.9 pounds over the course of 30 weeks with Novo Nordisk's current treatment Ozempic a ...Nov 8, 2022 · A scientist works at a Pfizer vaccine research and development facility. For drugmaker Pfizer, a fortune amassed in the COVID pandemic is now paving the path to pharma nirvana: a weight loss pill ... Pfizer is in early talks to acquire cancer drugmaker Seagen in a potentially multibillion-dollar deal, The Wall Street Journal reported Monday. Jump to Drug giant Pfizer is in early talks to buy cancer-focused biotech Seagen in what could b...Reprints. Investor’s rabid excitement over a new class of obesity medications has shifted focus in recent weeks, away from the injectables already arriving on the market, and toward the pills ...People with obesity or who were overweight and had another health problem lost an average of 15.1% of their body weight when assigned to take the pill, compared with a 2.4% loss in a group given a ...Dec 1, 2023 · Pfizer Inc. is dropping development of an experimental weight-loss pill due to side effects, a blow to the drugmaker’s efforts to find new avenues for growth. More than half of patients in... 2 days ago · Pfizer' s twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The ... June 26 (Reuters) - Pfizer Inc (PFE.N) said it is scrapping its once-a-day experimental obesity pill because of concerns about liver safety, but will continue developing its other obesity pill,...A scientist works at a Pfizer vaccine research and development facility. For drugmaker Pfizer, a fortune amassed in the COVID pandemic is now paving the path to pharma nirvana: a weight loss pill ...Pfizer scientists knew they wanted to make an antiviral that would go after the main protease (also known as the 3CL protease) of SARS-CoV-2—the coronavirus that causes COVID-19. Inhibiting a ...Nothing for the first 4 prescription fills or refills when you switch from certain brand name drugs to specific generic drugs. Specialty Pharmacy Tier 2 (Preferred specialty): 40% of our allowance ( $350 maximum) for a 30-day supply; $1,050 maximum for 31 to 90-day supplyOn the stock market today, PFE stock fell 5% to 28.91. Pfizer said the trial showed weight loss of up to 13% at 32 weeks in adults with obesity. But up to 73% of patients in the trial has nausea ...May 8, 2023 · An obesity therapy "is going to be one of the main drugs for Pfizer moving forward," Sessa said. ... The United States is expected to account for as much as 90% of weight-loss drug sales due to ... Found’s research revealed that 69% of its patient population do not have coverage for GLP-1 drugs to treat diabetes or for weight loss. This constituted a 50% decline in coverage since December ...Data from the Phase 2b trial of the weight-loss pill danuglipron is Pfizer’s best shot at changing the narrative. Investors have shown little enthusiasm so far for …Weight loss with Ozempic or Wegovy requires patients to inject themselves with the medication — a reported drawback for some people. But a new oral drug from Pfizer shows promise for delivering similar results, minus the needle. While some headlines have already proclaimed it as potentially “the next Ozempic in pill form” and more “user ...Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects. In this video. PFE -1.12 (-3.68%) Share.By Berkeley Lovelace Jr. The weight-loss drug Wegovy can reduce the risk of heart attacks and strokes by 20% in adults with heart disease and obesity, according to new research. The trial is the ...Pfizer (PFE) added ~4% on peer-reviewed Phase 2 data highlighting the weight loss effects of the company’s oral GLP-1 receptor agonist danuglipron. Read more here.Pfizer is continuing to advance the first full agonist oral GLP-1-RA candidate danuglipron toward late-state development. Danuglipron is the largest oral, small …Obesity is a serious health condition characterized by excess weight or body fat that may affect an individual’s health. Obesity has been associated with more than 200 health-related complications affecting every organ system in the body including type 2 diabetes, high blood pressure, cardiovascular disease, sleep apnea, joint pain, and cancer, among other diseases. 1,2,3,4 Jun 26, 2023 · Pfizer CEO Albert Bourla has said an obesity pill could eventually be a $10-billion-a-year product for Pfizer. The company's shares have dropped around 29% so far this year as it works to develop ... Dec 1, 2023 · On the stock market today, PFE stock fell 5% to 28.91. Pfizer said the trial showed weight loss of up to 13% at 32 weeks in adults with obesity. But up to 73% of patients in the trial has nausea ... Dec 1, 2023 · Pfizer said on Friday it was stopping further trials of a twice-daily version of its oral weight-loss drug, danuglipron, dealing a blow to its hopes of becoming an early contender in a market that ... Dec 1 (Reuters) - Pfizer (PFE.N) said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients dropped out of...The weight-loss drug that it contains, semaglutide, is a potent treatment for obesity, and Hollywood and TikTok celebrities have turned it into a sensation. ... Pfizer doesn’t have any weight ...Nov. 11, 2023. A pivotal new study suggests that the weight loss drug Wegovy cut the risk of heart attack, stroke or death from cardiovascular issues by 20 percent among overweight or obese people ...Pfizer’ s twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The ...Jun 26, 2023 · Pfizer will move ahead with a pill version of a weight-loss drug as competition heats up for an oral medication that can rival Ozempic and other GLP-1 drugs. ... “This is a big setback” for ... Mean weight loss was ~5%, with 15.5% of patients achieving weight loss greater than 10% relative to 5.8% receiving liraglutide 1.8 mg. SAR425899 has completed phase I trials in healthy volunteers ...The search for effective and safe weight loss treatment seems never-ending. But the newest anti-obesity medication, semaglutide, is still making waves more than a year after its 2021 approval by the U.S. Food and Drug Administration. The injectable drug, initially only used as diabetes medication, is the first drug since Saxenda (2014) …Video Transcript. - Meantime, Pfizer is entering the weight loss drug space for the first time. On Monday, a new peer-reviewed study of Pfizer's phase II clinical trial results showed that Pfizer ...Pfizer weight loss drug, fund management course, what is a gold back
4 ngày trước ... Pfizer said on Friday (Dec 1) it would not advance a twice-daily version of oral weight-loss drug Danuglipron into late-stage studies after .... Pfizer weight loss drug
here vacation rental investment24 thg 5, 2023 ... Pfizer's weight loss drug might be the new Ozempic, study suggests ... An oral weight-loss drug from Pfizer causes the same amount of weight loss ...Pfizer scientists knew they wanted to make an antiviral that would go after the main protease (also known as the 3CL protease) of SARS-CoV-2—the coronavirus that causes COVID-19. Inhibiting a ...Dive Brief: Pfizer will not advance a twice-daily dose of an experimental obesity drug into further testing after results from a mid-stage study showed high rates of gastrointestinal side effects and participant dropout. Treatment did lead to significant weight loss compared to placebo over the course of the Phase 2b study.Pfizer, Amgen and other pharmaceutical companies are rushing to develop weight-loss drugs, though they may not be available for another year or more. Barclays predicts a $100 billion global market ...The early data, while exciting, are far from conclusive. On Monday (Nov. 9), the dynamic drug company duo of Pfizer and BioNTech announced that early results from their late-stage Covid-19 vaccine clinical trial showed their jabs were 90% e...Pfizer will move ahead with a pill version of a weight-loss drug as competition heats up for an oral medication that can rival Ozempic and other GLP-1 drugs. ... “This is a big setback” for ...The drug did help participants lose as much as 13 per cent of their body weight over 32 weeks, a significant amount but less than the approved injectables from …Pfizer’ s twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The ...Pfizer Inc. is dropping development of an experimental weight-loss pill due to side effects, a blow to the drugmaker’s efforts to find new avenues for growth. More than half of patients in...The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. ... Pfizer Distributed by Pharmacia & Upjohn Co Division of Pfizer Inc, NY, NY 10017. DIDREX benzphetamine hydrochloride tablet: Product Information:Pfizer said the drug cut weight by as much as 13% at 32 weeks in adults with obesity and without type 2 diabetes in a mid-stage trial. That compares with 15% for Eli Lilly's experimental oral drug ...Pfizer scientists knew they wanted to make an antiviral that would go after the main protease (also known as the 3CL protease) of SARS-CoV-2—the coronavirus that causes COVID-19. Inhibiting a ...Pfizer has said that oral weight-loss drugs will capture a third of the obesity market. The company had pinned its weight-loss hopes on danuglipron after discontinuing another experimental obesity drug in June due to safety concerns. The study enrolled 630 patients with obesity across the US, Canada, Japan and Taiwan, who received the ...Dec 1, 2023 · Pfizer's discontinuation of its weight loss drug raises concerns and hurts share price, while Eli Lilly stock trends higher. ... demonstrating the value of having a horse in the GLP-1 weight loss ... May 22, 2023 · People with obesity or who were overweight and had another health problem lost an average of 15.1% of their body weight when assigned to take the pill, compared with a 2.4% loss in a group given a ... Pfizer’ s twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The ...The decision by the Food and Drug Administration on Wednesday to approve the weight loss drug tirzepatide adds a potent new tool to the fast-growing arsenal of obesity drugs.. The drug, which will ...Being healthy is simple, right? "Eat less, move more." That's easy to say, but practicality is one of the most important things when it comes to health and fitness. Recommendations like this are blanket statements that don't address practic...Now, Pfizer stock rising as participants were able to lose about 10 pounds over the course of 16 weeks versus 9.9 pounds over the course of 30 weeks with Novo Nordisk's current treatment Ozempic a ...May 23, 2023 · Novo Nordisk's weight-loss drug semaglutide, sold as the once-weekly Wegovy shot, was effective as a daily pill in a new study. ... The Pfizer study was smaller than Novo’s late-stage trial and ... First-to-market Wegovy, which launched in the U.S. in June 2021, leads to an average weight loss of 15% when combined with changes in diet and exercise. Novo, Lilly and other big drugmakers ...The weight-loss drug will list for $1,059.87 for a month’s supply. It will be available by year end. Lilly’s shares rose less than 1% at 12:33 p.m. in New York.To determine weight-loss percentage, the current weight is subtracted from the original weight. Then, that answer is multiplied by 100. That answer is divided by the original weight.Pfizer CEO Albert Bourla has said that an obesity pill could eventually generate $10 billion each year for the company. Lotiglipron, danuglipron and Novo Nordisk 's blockbuster weight loss ...The pharmaceutical drug-based weight-reduction market is in full expansion mode in 2023. The global anti-obesity drug market is projected to grow from $4.5 billion in 2023 to $22.9 billion by 2030 ...Redotex is a drug that is sometimes prescribed or recommended as a weight loss aid. It is produced in Mexico by the Medix pharmaceutical company and is banned in a number of countries, including the United States.Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides 8:10 AM ET Pfizer said Friday it would not advance development of a twice-daily oral weight-loss drug because of its side ...May 23, 2023 · The Big Pharma is pivoting Mounjaro into a weight loss drug, much like Novo did with Ozempic and Wegovy. Lilly’s therapy, which could be approved in obesity later this year and launch in late ... Español. Today, the U.S. Food and Drug Administration approved Wegovy (semaglutide) injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at least ...Contrave. as low as. $607. View other Opioid Antagonist / Atypical Antidepressant Combinations. Contrave ( naltrexone / bupropion) is a combination product used to promote and maintain weight loss in obese adults or overweight adults who have weight related medical problems. Contrave should be used with diet and exercise.Español. Today, the U.S. Food and Drug Administration approved Wegovy (semaglutide) injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at least ...Español. Today, the U.S. Food and Drug Administration approved Wegovy (semaglutide) injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at least ...Mar 5, 2023 · New weight loss drugs are changing the narrative on obesity, with a push from pharma. By Elaine Chen and Matthew Herper. March 5, 2023. ... Pfizer, which is developing an oral GLP-1, estimates the ... First-to-market Wegovy, which launched in the U.S. in June 2021, leads to an average weight loss of 15% when combined with changes in diet and exercise. Novo, Lilly and other big drugmakers ...2 days ago · While this category of weight loss drugs is known to cause gastrointestinal symptoms such as nausea, vomiting, and diarrhoea — and more severe ones such as stomach paralysis — the rates with Pfizer’s danuglipron were higher. Pfizer’s statement said that at 32 weeks, up to 73% experienced nausea, 47% vomiting, and 25% diarrhoea. Friday’s stock losses tied to pessimism about Pfizer’s weight loss drug potential builds on the narrative hanging over the pharmaceutical giant for all of 2023, as sales dry up in its once ...Pfizer CEO Albert Bourla has said that an obesity pill could eventually generate $10 billion each year for the company. Lotiglipron, danuglipron and Novo Nordisk 's blockbuster weight loss ...Jun 7, 2023 · How Pfizer's Weight-Loss Pill Compares to Ozempic Injections Weight loss with Ozempic or Wegovy requires an injection, but Pfizer is developing a similar drug in pill form. What... Dec 1, 2023 · Pfizer stock was falling Friday after the biopharmaceutical company announced that it will not be moving forward with a Phase 3 trial of its weight loss candidate. Pfizer said in a news release ... June 26 (Reuters) - Pfizer Inc (PFE.N) said it is scrapping its once-a-day experimental obesity pill because of concerns about liver safety, but will continue developing its other obesity pill,...If you are on a weight loss journey, you have probably heard about the importance of creating a calorie deficit. A calorie deficit occurs when you consume fewer calories than your body needs to maintain its current weight.Published September 13, 2023. Medicare doesn’t cover drugs prescribed for weight loss but it covers Ozempic, an FDA-approved diabetes drug that’s unintentionally become popular for weight loss. Medicare Part D covers Ozempic for diabetes, not for obesity. The 2003 Medicare Part D law for prescription drug coverage specifically excludes ...Dec 1, 2023 · Pfizer stock was falling Friday after the biopharmaceutical company announced that it will not be moving forward with a Phase 3 trial of its weight loss candidate. Pfizer said in a news release ... Improvements were seen at all dose levels, but the highest results were achieved by patients who received 120 mg doses of the drug. Those patients saw an average reduction in body weight of about 18 …Zepbound is the second drug in a new class of obesity medications to be approved for weight loss, following Wegovy. And it is now likely the most effective …Pfizer's decision not to advance danuglipron into Phase 3 studies marks a critical juncture, particularly as the company eyes a $10 billion opportunity in the weight loss drug sector. Pfizer ...An oral weight-loss drug from Pfizer causes the same amount of weight loss as its competitor Novo Nordisk’s injection Ozempic, according to a peer-reviewed study released Monday. The results ...The decision by the Food and Drug Administration on Wednesday to approve the weight loss drug tirzepatide adds a potent new tool to the fast-growing arsenal of obesity drugs.. The drug, which will ...3 ngày trước ... Pfizer has struggled to develop a pill to join the makers of Ozempic and Mounjaro in the weight-loss gold rush.Pfizer said Friday it was stopping development of a twice-daily oral obesity medication, a blow to the company’s efforts to compete in the booming weight loss field.Pfizer CEO Albert Bourla has said that an obesity pill could eventually generate $10 billion each year for the company. Lotiglipron, danuglipron and Novo Nordisk 's blockbuster weight loss ...Lotiglipron offered Pfizer a chance to match the dosing regimen of Lilly’s orforglipron, which triggered 14.7% weight loss at 36 weeks, and Novo’s oral semaglutide.Dec 1, 2023 · PFE Stock: Playing Catch-Up For Weight Loss Drugs. Pfizer said the trial showed weight loss of up to 13% at 32 weeks in adults with obesity. But up to 73% of patients in the trial has nausea, up ... . Us steel prices chart, oxy stock buy or sell